Sanofi's SAR444881 tumor trial results posted after early stop; hemophilia study recruitsSep 29Weekly roundup, 2 itemsSanofi
Kaiser Permanente registers COVID vaccine choice messaging trial with Sanofi as collaboratorSep 24Trial updateSanofi
Sanofi registers Phase 2b hidradenitis suppurativa trial; RSV+HMPV vaccine study recruitingSep 10Weekly roundup, 2 itemsduvakitugSanofi
Sanofi's itepekimab COPD mechanism study AERIFY-3 posts results after 2025 completionAug 31Trial updateitepekimabRegeneron Pharmaceuticals
FDA approves labeling supplement for Children's Xyzal Allergy 24HR oral solutionAug 31Regulatory decisionlevocetirizineSanofi
Sanofi registers Phase 3 extension study for lunsekimig in COPD, named COLOSSUSAug 28Trial updatelunsekimigSanofi
Sanofi advances belumosudil Phase 3 in cGVHD; H5N8 flu vaccine study recruitingAug 21Weekly roundup, 2 itemsbelumosudilSanofi
Yale registers Gaucher natural history study with Sanofi collaborationAug 11Weekly roundup, 2 itemsSanofi
Novavax raises 2026 revenue outlook, flags Sanofi trial talks and C. diff progressAug 6Quarterly updateNovavaxSanofi
Sanofi posts results across four trials; RSV toddler study OPAL ended early by sponsor decisionAug 6Weekly roundup, 4 itemsrilzabrutinibSanofi
Results post for old USC gastric cancer trial; Bristol Myers Squibb opens new Zeposia PML studyJul 30Weekly roundup, 3 itemsBristol Myers Squibbiberdomide
Sanofi registers alirocumab cardiovascular outcomes study; RSV+HMPV vaccine trial recruitingJul 30Weekly roundup, 3 itemsalirocumabSanofi
Sanofi's week: AVAPRO label update, new belumosudil BE study, two TB trial results postedJul 24Weekly roundup, 6 itemsbelumosudilirbesartan
Sanofi posts rilzabrutinib atopic dermatitis results; opens Phase 3 meningococcal vaccine trial in CJul 17Weekly roundup, 2 itemsrilzabrutinibSanofi
Regeneron registers Phase 3 PICC clot-prevention trial; Sanofi runs sarilumab study as collaboratorJul 17Weekly roundup, 3 itemsamrecibartcenvacibart
FDA approves subcutaneous Sarclisa Escena with on-body injector for multiple myelomaJul 15Regulatory decisionisatuximabisatuximab-irfc
Lakefront board member Fontoura resigns after Sanofi names him R&D chiefJul 13PeopleLakefront Biotherapeutics NVSanofi
FDA approves Sarclisa Escena, a new dosage form from SanofiJul 9Regulatory decisionisatuximabisatuximab-irfc
Sign in